Skip to main content
Clinical Trials/NCT06089421
NCT06089421RecruitingNot Applicable

A Prospective, Randomized Trial to Compare Telegenetics to Counseling Via a Novel Genetic Information Assistant in High-risk Cancer Patients.

University of Virginia2 sites in 1 country96 target enrollmentStarted: April 1, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
96
Locations
2
Primary Endpoint
To assess feasibility of using a chatbot (GIA) for pre-test genetic counseling compared to standard of care GC

Study Overview

Brief Summary

The goal of this clinical trial is to learn about different ways cancer genetic screening can be provided to rural communities in participants at high risk for certain cancers. The main question it aims to answer is:

• Does receiving pre-genetic test education with a chat bot or genetic counselor affect if the participant decides to get genetic testing?

Participants will:

  • have a pre-test genetic counselling session with a genetic counselor or the GIA chatbot
  • answer questions about their cancer genetic knowledge and how they are doing
  • provide a saliva sample for genetic testing to test for cancer gene mutations
  • have their genetic testing results provided to them.
  • have the option to share their genetic testing results with family members

Researchers will compare how many participants who had pre-genetic counseling with the chatbot received genetic testing to how many participants who had pre-genetic counseling with a genetic counselor received genetic testing.

Detailed Description

High risk patients will be randomized to standard of care telegenetics with a UVA Genetic Counselor (GC) for pre-test counseling or to the novel interventional arm of pre-test counseling via Genetic Information Assistant (GIA). Participants in the study will receive their link for a telegenetics appointment or GIA link based on randomization and patients will complete pre-test genetic counseling via their assigned treatment arm. Participants will not be masked to their trial arm assignment. In the telegenetics arm, patients will be offered a video visit scheduled through Epic zoom or a phone visit in our cancer genetics clinic per standard of care. Patients randomized to the GIA arm will receive a personalized link based on their family history. At the completion of counseling, participants will be offered genetic testing. If they agree, they will be mailed a saliva kit via Invitae Genetics for panel based genetic testing via The Invitae Common Hereditary Cancers panel to analyze 47 genes associated with cancers of the breast, ovary, uterus, and gastrointestinal system, which includes the stomach, colon, rectum, small bowel, and pancreas.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Screening
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •At high risk for having a genetic pathogenic variant as assessed by a GC or physician according to the NCCN guidelines
  • •Provision of signed and dated informed consent form.
  • •Stated willingness to comply with all study procedures and availability for the duration of the study.
  • •Male or female, aged 18 and over.
  • •Subjects must have a smartphone with access to cellular and/or internet service or a computer with internet service.
  • •Subjects must have technological competency/proficiency to use their Smartphone and/or computer in conjunction with the communication aid GIA.

Exclusion Criteria

  • •Cannot communicate in English or Spanish.
  • •Subjects must not have completed panel-based cancer genetic testing in the past.

Arms & Interventions

Standard of care telegenetics with a UVA genetic counselor (GC) for pre-test counseling

Active Comparator

Pre-genetic test counselling with a genetic counselor from the University of Virginia

Intervention: Telegenetics with UVA genetic counselor (Other)

Novel interventional arm of pre-test counseling via GIA

Experimental

Pre-genetic test counselling through novel chat bot Genetic Information Assistant (GIA)

Intervention: Genetic Information Assistant (Other)

Outcomes

Primary Outcomes

To assess feasibility of using a chatbot (GIA) for pre-test genetic counseling compared to standard of care GC

Time Frame: 3 months

dichotomous measurement of whether the randomized participant completes genetic testing within three months.

Secondary Outcomes

  • To assess differences of SURE scale(6 months)
  • To assess differences of Decisional Conflict scale(6 months)
  • To assess differences of Comprehensive Score of Financial Toxicity scale(6 months)
  • To assess differences of Multi-dimensional Impact of Cancer Risk Assessment (MICRA) scale(6 months)
  • To test cancer knowledge following the pre-test genetic counseling with GIA versus GC(3 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Kari Ring, MD

Assistant Professor

University of Virginia

Study Sites (2)

Loading locations...

Similar Trials

Completed
Not Applicable
Effectiveness of AI Genetic Counseling Program vs In-person Genetic Counseling in Breast CancerBreast Cancer
NCT04354675Case Comprehensive Cancer Center35
Active, not recruiting
Phase 2
Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast CancerAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast CarcinomaPrognostic Stage I Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage IB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8
NCT01334021M.D. Anderson Cancer Center1,100
Unknown
Not Applicable
A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient CareArthritisMental DisordersCardiovascular DiseasesChronic PainPainDiabetes Mellitus, Type 2
NCT02487888Proove Bioscience, Inc.100,000
Completed
Not Applicable
Streamlined Genetic Testing in Prostate CancerProstate Cancer
NCT04359758Georgetown University112
Completed
Not Applicable
Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH TrialRefractory Mantle Cell LymphomaRecurrent Mantle Cell Lymphoma
NCT04872413M.D. Anderson Cancer Center1